Survey of knowledge for diagnosing and managing prediabetes in Latin-America: cross-sectional study.

Diagnosis Knowledge Latin America Management Prediabetes

Journal

Diabetology & metabolic syndrome
ISSN: 1758-5996
Titre abrégé: Diabetol Metab Syndr
Pays: England
ID NLM: 101488958

Informations de publication

Date de publication:
2019
Historique:
received: 29 08 2019
accepted: 28 11 2019
entrez: 13 12 2019
pubmed: 13 12 2019
medline: 13 12 2019
Statut: epublish

Résumé

Prediabetes has been proposed as a risk factor for the development of type 2 diabetes mellitus (DM2) and cardiovascular disease (CVD). Despite the clinical importance of prediabetes, little is known about the level of knowledge, beliefs and barriers to screening and treating prediabetes amongst care health providers in Latin America. The aim of the present survey was to evaluate the knowledge and beliefs about prediabetes amongst in Latin American health care providers. In a cross-sectional study, we adapted the written survey designed by the Johns Hopkins University group, and applied it to health care providers across Latin America during three meetings, in 2017, and with physicians from primary care centers in Bucaramanga, Colombia convened in 2017. The survey consisted of questions under four headings, diabetes screening, management of prediabetes, pharmacological treatment-metformin use, and demographic information. We perform a descriptive analysis to determine the differences in responses between different medical specialties. The majority of the care providers that answered the survey were Colombian physicians, 54.5% of respondents had 10 years or more since completing their training and more women responded. Only 9.5% identified the 12 prediabetes risk factors described in the literature. The most common risk factor identified was a family history of diabetes, followed by overweight, a sedentary lifestyle and dyslipidemia, while ethnicity was the risk factor least commonly. 47.1% answered that laboratory tests to detect prediabetes are fasting glucose and HbA1C, 82.5% correctly identified fasting plasma glucose as the best test, 35.9% correctly responded that to the recommended weight loss goal is 5 to 7% and 49.1% that 150 min is considered the minimum level of physical activity per week. 78% agreed that the identification and treatment of prediabetes is important. 56% believed that patients with prediabetes progress more rapidly to diabetes and 40.6% considered that metformin could reduce the risk of diabetes in patients already diagnosed with prediabetes. These results demonstrate that there are important gaps in the knowledge of the diagnosis, clinical implications and management of prediabetes amongst Latin America health providers.

Sections du résumé

BACKGROUND BACKGROUND
Prediabetes has been proposed as a risk factor for the development of type 2 diabetes mellitus (DM2) and cardiovascular disease (CVD). Despite the clinical importance of prediabetes, little is known about the level of knowledge, beliefs and barriers to screening and treating prediabetes amongst care health providers in Latin America. The aim of the present survey was to evaluate the knowledge and beliefs about prediabetes amongst in Latin American health care providers.
METHODOLOGY METHODS
In a cross-sectional study, we adapted the written survey designed by the Johns Hopkins University group, and applied it to health care providers across Latin America during three meetings, in 2017, and with physicians from primary care centers in Bucaramanga, Colombia convened in 2017. The survey consisted of questions under four headings, diabetes screening, management of prediabetes, pharmacological treatment-metformin use, and demographic information. We perform a descriptive analysis to determine the differences in responses between different medical specialties.
RESULTS RESULTS
The majority of the care providers that answered the survey were Colombian physicians, 54.5% of respondents had 10 years or more since completing their training and more women responded. Only 9.5% identified the 12 prediabetes risk factors described in the literature. The most common risk factor identified was a family history of diabetes, followed by overweight, a sedentary lifestyle and dyslipidemia, while ethnicity was the risk factor least commonly. 47.1% answered that laboratory tests to detect prediabetes are fasting glucose and HbA1C, 82.5% correctly identified fasting plasma glucose as the best test, 35.9% correctly responded that to the recommended weight loss goal is 5 to 7% and 49.1% that 150 min is considered the minimum level of physical activity per week. 78% agreed that the identification and treatment of prediabetes is important. 56% believed that patients with prediabetes progress more rapidly to diabetes and 40.6% considered that metformin could reduce the risk of diabetes in patients already diagnosed with prediabetes.
CONCLUSION CONCLUSIONS
These results demonstrate that there are important gaps in the knowledge of the diagnosis, clinical implications and management of prediabetes amongst Latin America health providers.

Identifiants

pubmed: 31827627
doi: 10.1186/s13098-019-0500-4
pii: 500
pmc: PMC6894241
doi:

Types de publication

Journal Article

Langues

eng

Pagination

102

Informations de copyright

© The Author(s) 2019.

Déclaration de conflit d'intérêts

Competing interestsThe authors declare that they have no competing interests.

Références

Diabetes Care. 2012 Apr;35(4):731-7
pubmed: 22442396
BMJ. 2016 Nov 23;355:i5953
pubmed: 27881363
Lancet. 2006 Nov 11;368(9548):1673-9
pubmed: 17098085
Clin Investig Arterioscler. 2016 Jan-Feb;28(1):9-18
pubmed: 26596523
Diabetologia. 2006 Feb;49(2):289-97
pubmed: 16391903
Diabetes Care. 2018 Jan;41(Suppl 1):S1-S2
pubmed: 29222369
Trials. 2017 Jul 25;18(1):351
pubmed: 28743313
Lancet. 2019 Oct 5;394(10205):1231-1242
pubmed: 31488369
Diabetes. 2017 Jan;66(1):158-169
pubmed: 27999110
J Gen Intern Med. 2017 Nov;32(11):1172-1178
pubmed: 28730532
Glob Heart. 2016 Mar;11(1):61-70
pubmed: 27102023
N Engl J Med. 2002 Feb 7;346(6):393-403
pubmed: 11832527
Rev Panam Salud Publica. 2017 Dec 12;41:e172
pubmed: 31410086
N Engl J Med. 2008 Oct 9;359(15):1577-89
pubmed: 18784090
Colomb Med (Cali). 2017 Dec 30;48(4):191-203
pubmed: 29662261
BMJ. 2017 Jan 4;356:i6538
pubmed: 28052845
Lancet Diabetes Endocrinol. 2015 Nov;3(11):866-75
pubmed: 26377054

Auteurs

Jennifer Garay (J)

Research Department, Fundacion Oftalmologica de Santander (FOSCAL) Internacional, Calle 158 # 20-95, Consultorio 101/102, Floridablanca, Santander Colombia.

Paul A Camacho (PA)

Research Department, Fundacion Oftalmologica de Santander (FOSCAL) Internacional, Calle 158 # 20-95, Consultorio 101/102, Floridablanca, Santander Colombia.
2Medical School, Universidad Autónoma de Bucaramanga (UNAB), Floridablanca, Colombia.

Jose Lopez-Lopez (J)

Research Department, Fundacion Oftalmologica de Santander (FOSCAL) Internacional, Calle 158 # 20-95, Consultorio 101/102, Floridablanca, Santander Colombia.

Juliana Alvernia (J)

Research Department, Fundacion Oftalmologica de Santander (FOSCAL) Internacional, Calle 158 # 20-95, Consultorio 101/102, Floridablanca, Santander Colombia.

Marcela Garcia (M)

Research Department, Fundacion Oftalmologica de Santander (FOSCAL) Internacional, Calle 158 # 20-95, Consultorio 101/102, Floridablanca, Santander Colombia.

Daniel D Cohen (DD)

Research Department, Fundacion Oftalmologica de Santander (FOSCAL) Internacional, Calle 158 # 20-95, Consultorio 101/102, Floridablanca, Santander Colombia.
3Instituto Masira, Medical School, Universidad de Santander (UDES), Bucaramanga, Colombia.

Carlos Calderon (C)

Fundación Santandereana de Diabetes (FUSANDE), Cra. 33 #46-45, Bucaramanga, Santander Colombia.

Patricio Lopez-Jaramillo (P)

Research Department, Fundacion Oftalmologica de Santander (FOSCAL) Internacional, Calle 158 # 20-95, Consultorio 101/102, Floridablanca, Santander Colombia.
2Medical School, Universidad Autónoma de Bucaramanga (UNAB), Floridablanca, Colombia.
3Instituto Masira, Medical School, Universidad de Santander (UDES), Bucaramanga, Colombia.
4Eugenio Espejo Medical School, Universidad UTE, Quito, Ecuador.

Classifications MeSH